Please use this link to access this publication. Abstract Background and Hypothesis Up to 43% of people with schizophrenia have a lifetime cannabis use disorder (CUD). Tetrahydrocannabinol (THC) has been…
Condition: Schizophrenia
Cannabis with high cannabidiol content is associated with fewer psychotic experiences
Abstract Objective Cannabis is associated with psychotic outcomes in numerous studies, an effect that is commonly attributed to Δ 9-tetrahydrocannabinol (Δ 9-THC). An increasing number of authors identify cannabidiol, another component…
THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia
Please use this link to access this publication. Abstract Cannabis use has been associated with an increased risk to develop schizophrenia as well as symptom exacerbation in patients. In contrast,…
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Please use this link to access this publication. Abstract Background and objectives Cognitive impairment is a core symptom domain of schizophrenia, neurological disorders and substance abuse. It is characterised by deficits in learning,…
Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
Abstract The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This…
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Please use this link to access this publication. Abstract Rationale Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been…
The level of evidence of medical marijuana use for treating disabilities: a scoping review
Please use this link to access this publication. Abstract Purpose: Twenty-nine states have bypassed federal regulations by legalizing marijuana (MJ) either medicinally, recreationally or both. The FDA states that there is…
Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis
Abstract The neurobiological mechanisms underlying the association between cannabis use and acute or long-lasting psychosis are not completely understood. While some evidence suggests altered striatal dopamine may underlie the association,…
Case Report: CBD Cigarettes for Harm Reduction and Adjunctive Therapy in a Patient With Schizophrenia and Substance Use Disorder
Abstract The treatment of patients with schizophrenia and substance use disorder poses a challenge for clinicians. Continued use of cannabis and cocaine can exacerbate psychotic symptoms and worsen the course…
Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies
Please use this link to access this publication. Abstract Rationale Antipsychotics help alleviate the positive symptoms associated with schizophrenia; however, their debilitating side effects have spurred the search for better…